HG
15 oct. 2018
Very well done and informative. I truly appreciate the Drug process in entirety being broken down into sections that are easy to comprehend. It is obvious the speakers were chosen for their knowledge.
KR
24 mai 2020
I am really glad to have course offered by california university . Its really helpful for me. And i am thankful to all lecturer, and teachers to explain overall drug development process.\n\nThank you!
par Krithika S K N
•2 sept. 2019
Was informative. The lectures could have been more structured and slides more detailed.
par Adrija C
•2 nov. 2020
US- centric course. The content in week 3 was not well explained and felt rushed.
par Aneesh T G
•23 août 2020
More emphasis on the filing and submissions and approvals need to be there
par Carolina S V
•27 déc. 2017
Weeks 1 and 2 are great, but the classes of week 3 need more organization.
par Damien V
•17 sept. 2018
good up to phase 2 (included). Phase 3 and after was less informative
par Sean K
•21 févr. 2022
Lot of outdated information and poor presentation slides
par Brian M
•25 avr. 2021
It's from 2013. Good overview but time for an update.
par Miguel M V
•31 août 2020
would like an specialization on this matter
par Budupula K
•19 juin 2021
I gained knowledge
par Sofia B J
•2 sept. 2020
goooooood
par Aman b
•15 sept. 2021
good
par DR. A G
•5 sept. 2020
good
par Pratiksha
•2 juin 2020
n
i
c
e
par Dale G Y
•24 août 2021
Had hoped to hear a better description of the types of trials and more about the Regulators' logic in deciding what trials a drug must have - PK for ANDA? BE for ANDA? P1 and P3 for 505B2? Does PK=P1? These topics are useful. Need to define these options and explain the reason for using them for different scenarios. That's part of what I expected from Drug Development.
The lecture style of second half was difficult. More structure, clear pronunciation, less random thoughts about unexplained topics.
par Mohamed T H
•18 juil. 2020
Phase 1 was explained nicely. But phase 2 description was unclear with some diagrams with not much context and a lot of acronyms thrown around. Did not learn a lot about phase 3 either. The presentation slides were very busy like the previous course.
par Malamati V
•23 oct. 2020
I felt like the lectures were not so organized as far as their material is concerned. I also found the overall course more "business-oriented" than actually educational.
par Nayanika P
•8 janv. 2022
Okayish. I wouldn't recommend this. If you're really passionate about Drug Development and it's clinical aspects, try and find better courses.
par Alejandro G
•28 mai 2020
The course was not structured as an online course. the slides were quite boring and some of the speakers were not enthusiastic
par Arash Y
•3 mars 2018
Presentation slides and sound quality is at its lowest.
par Maria B
•18 mars 2020
The course is not prepared for online course
par Benoit E
•21 févr. 2019
A lot too much bla bla on the Phase iv part
par Michael M
•9 sept. 2020
I only looked at the slides, as I wanted to confirm, what I read in some of the reviews. A standard issue on Coursera is, that material is not maintained and updated. I have worked in the pharmaceutical industry for more than 15 years now and everything is constantly evolving. The world of 2013 is not the world of 2020 and course material should e updated regularly.
par Ananya S
•13 juil. 2020
The data shown in the lecture and even the lecture itself is dated back to 2012. Kindly upload an updated lecture with new rules, recent data, recent examples. It would be of great help.
par 19BBT051-SHARVAISH D R B B
•19 sept. 2020
Nice very important
par Ramani D
•24 mai 2020
Thank u so much